Literature DB >> 10421442

A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate.

T L Rosenberry1, W D Mallender, P J Thomas, T Szegletes.   

Abstract

The active site gorge of acetylcholinesterase (AChE) contains two sites of ligand binding, an acylation site near the base of the gorge and a peripheral site at its mouth. We recently introduced a steric blockade model which demonstrated that small peripheral site ligands like propidium can inhibit substrate hydrolysis simply by decreasing the substrate association and dissociation rate constants without altering the equilibrium constant for substrate binding to the acylation site. We now employ our nonequilibrium kinetic analysis to extend this model to include blockade of the dissociation of substrate hydrolysis products by bound peripheral site ligand. We also report here that acetylthiocholine can bind to the AChE peripheral site with an equilibrium dissociation constant K(S) of about 1 mM. This value was determined from the effect of the acetylthiocholine concentration on the rate at which fasciculin associates with the peripheral site. When substrate binding to the peripheral site is incorporated into our steric blockade model, hydrolysis rates at low substrate concentration appear to be accelerated while substrate inhibition of hydrolysis occurs at high substrate concentration. The model predicts that hydrolysis rates for substrates which equilibrate with the acylation site prior to the acylation step should not be inhibited by bound peripheral site ligand. Organophosphates equilibrate with AChE prior to phosphorylating the active site serine residue, and as predicted propidium had little effect on the phosphorylation rate constants for the fluorogenic organophosphate ethylmethyl-phosphonylcoumarin (EMPC). The 2nd-order phosphorylation rate constant kOP/K(OP) was decreased 3-fold by a high concentration of propidium and the 1st-order rate constant kOP increased somewhat. In contrast to propidium, when the neurotoxin fasciculin bound to the AChE peripheral site both a steric blockade and a conformational change in the acylation site appeared to occur. With saturating fasciculin, kOP/K(OP) decreased by a factor of more than 750 and kOP decreased 300-fold. These data suggest that new peripheral site ligands may be designed to have selective effects on AChE phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421442     DOI: 10.1016/s0009-2797(99)00017-4

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  12 in total

1.  Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.

Authors:  Cédric Lecoutey; Damien Hedou; Thomas Freret; Patrizia Giannoni; Florence Gaven; Marc Since; Valentine Bouet; Céline Ballandonne; Sophie Corvaisier; Aurélie Malzert Fréon; Serge Mignani; Thierry Cresteil; Michel Boulouard; Sylvie Claeysen; Christophe Rochais; Patrick Dallemagne
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

2.  Structural insights into substrate traffic and inhibition in acetylcholinesterase.

Authors:  Jacques-Philippe Colletier; Didier Fournier; Harry M Greenblatt; Jure Stojan; Joel L Sussman; Giuseppe Zaccai; Israel Silman; Martin Weik
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

Review 3.  Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs.

Authors:  Yvonne Rosenberg; Ashima Saxena
Journal:  Neuropharmacology       Date:  2020-05-19       Impact factor: 5.250

4.  Protection against paraoxon toxicity by an intravenous pretreatment with polyethylene-glycol-conjugated recombinant butyrylcholinesterase in macaques.

Authors:  Yvonne J Rosenberg; Jeffery Gearhart; Lingjun Mao; Xiaoming Jiang; Segundo Hernandez-Abanto
Journal:  Chem Biol Interact       Date:  2013-12-30       Impact factor: 5.192

5.  Role of acetylcholinesterase on the structure and function of cholinergic synapses: insights gained from studies on knockout mice.

Authors:  Michael Adler; Richard E Sweeney; Tracey A Hamilton; Oksana Lockridge; Ellen G Duysen; Angela L Purcell; Sharad S Deshpande
Journal:  Cell Mol Neurobiol       Date:  2011-05-03       Impact factor: 5.046

6.  An evaluation of the inhibition of human butyrylcholinesterase and acetylcholinesterase by the organophosphate chlorpyrifos oxon.

Authors:  Josephine Shenouda; Paula Green; Lester Sultatos
Journal:  Toxicol Appl Pharmacol       Date:  2009-08-19       Impact factor: 4.219

7.  Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity.

Authors:  Daniel Silva; Mourad Chioua; Abdelouahid Samadi; Paula Agostinho; Pedro Garção; Rocío Lajarín-Cuesta; Cristobal de Los Ríos; Isabel Iriepa; Ignacio Moraleda; Laura Gonzalez-Lafuente; Eduarda Mendes; Concepción Pérez; María Isabel Rodríguez-Franco; José Marco-Contelles; M Carmo Carreiras
Journal:  ACS Chem Neurosci       Date:  2013-02-04       Impact factor: 4.418

Review 8.  Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger.

Authors:  Yvonne J Rosenberg; James B Fink
Journal:  Ann N Y Acad Sci       Date:  2016-07-02       Impact factor: 5.691

9.  Pulmonary delivery of an aerosolized recombinant human butyrylcholinesterase pretreatment protects against aerosolized paraoxon in macaques.

Authors:  Yvonne J Rosenberg; Beth Laube; Lingjun Mao; Xiaoming Jiang; Segundo Hernandez-Abanto; Keunmyoung D Lee; Robert Adams
Journal:  Chem Biol Interact       Date:  2012-11-21       Impact factor: 5.192

10.  Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: an atypical butyrylcholinesterase from the Medaka Oryzias latipes.

Authors:  Leo Pezzementi; Florian Nachon; Arnaud Chatonnet
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.